Incretin-based drugs and adverse pancreatic events: Almost a decade later and uncertainty remains

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 951-953

  Azoulay, Laurent ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LIRAGLUTIDE; PLACEBO; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ACUTE PANCREATITIS; BODY WEIGHT; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS CANCER; PANCREAS DISEASE; PANCREATITIS; RISK FACTOR; CASE CONTROL STUDY; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PANCREAS;

BODY WEIGHT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PANCREAS; PANCREATITIS;

EID: 84946035690     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0347     Document Type: Note

References (24)

1. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.
2. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126-2132.
3. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1- based therapies. Gastroenterology 2011;141: 150-156.
4. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013;50:569-577.
5. Faillie JL, Babai S, Cŕepin S, et al.; French Pharmacovigilance Centers Network. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol 2014;51:491-497.
6. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019- 1027.
7. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33:2349-2354.
8. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13:559-566.
9. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012;14:904-911.
10. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29:1412-1418.
11. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013;346:f2267.
12. Funch D, Gydesen H, Tornøe K, Major- Pedersen A, Chan KA. A prospective, claimsbased assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 2014;16:273-275.
13. Giorda CB, Picariello R, Nada E, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a casecontrol study. Lancet Diabetes Endocrinol 2014;2: 111-115.
14. Faillie JL, Azoulay L, Patenaude V, Hillaire- Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014;348:g2780.
15. Chou HC, Chen WW, Hsiao FY. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested casecontrol study. Drug Saf 2014;37:521-528.
16. Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care 2015;38:1089-1098.
17. Gonzalez-Perez A, Schlienger RG, Rodŕiguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a populationbased cohort study. Diabetes Care 2010;33: 2580-2585.
18. Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35:2665-2673.
19. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009;20: 488-495.
20. Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 2015;38:1058-1066.
21. Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf 2012;3: 157-164.
22. Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Sẗurmer T. Dipeptidyl-peptidase- 4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab 2014;16:1247- 1256.
23. Suissa S, Henry D, Caetano P, et al.; Canadian Network for Observational Drug Effect Studies (CNODES). CNODES: The Canadian Network for Observational Drug Effect Studies. Open Med 2012;6:e134-e140.
24. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439.